StemInov has successfully raised €300,000 in equity as part of a €2 million funding round aimed at advancing its pioneering biopharmaceutical therapies for severe inflammatory conditions.

Information on the Target

StemInov, founded in 2019, is a pioneering biopharmaceutical company specializing in therapies that utilize mesenchymal stem cells for the treatment of inflammatory and autoimmune diseases. The company is focused on addressing a significant unmet medical need related to severe inflammatory conditions, specifically targeting acute respiratory distress syndrome, which is a leading cause of death in intensive care units.

As these diseases are among the top causes of mortality in intensive care settings and the tenth leading cause of death in developed countries, there is a critical demand for innovative treatment options. Globally, a person succumbs to complications from infections every 3 to 4 seconds, highlighting the urgency of StemInov's mission.

Industry Overview in France

The French biopharmaceutical industry is a robust sector that has been growing steadily, supported by strong public and private investments. With a focus on innovation, French companies are at the forefront of d